Hutchmed (China) Limited - American Depositary Shares (HCM) closed at $13.27 on November 2, 2026, up 0.9% from the previous close, on volume of 47,666 shares (30-day average 50,704).
Data as of November 2, 2026.
Globe Newswire (Sun, 1-Nov 7:00 PM ET)
HUTCHMED (China) (HCM) Gets a Buy from Orient Securities
TipRanks (Sun, 1-Nov 5:36 PM ET)
GF Securities Sticks to Its Buy Rating for HUTCHMED (China) (HCM)
TipRanks (Sat, 31-Oct 1:25 AM ET)
Huatai Securities Remains a Buy on HUTCHMED (China) (HCM)
TipRanks (Thu, 29-Oct 3:39 AM ET)
Globe Newswire (Wed, 28-Oct 8:00 PM ET)
HUTCHMED Sets November 5 Webcast to Spotlight Phase III Savolitinib Data in MET-Driven NSCLC
Market Chameleon (Tue, 27-Oct 3:15 AM ET)
Globe Newswire (Mon, 26-Oct 8:00 PM ET)
Globe Newswire (Mon, 26-Oct 4:30 AM ET)
Globe Newswire (Sun, 25-Oct 8:00 PM ET)
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Globe Newswire (Tue, 20-Oct 8:00 PM ET)
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Hutchmed (China) Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol HCM.
As of November 3, 2026, HCM stock price declined to $13.10 with 14,674 million shares trading.
HCM has a beta of 1.13, meaning it tends to be more sensitive to market movements. HCM has a correlation of 0.12 to the broad based SPY ETF.
HCM has a market cap of $2.28 billion. This is considered a Mid Cap stock.
In the last 3 years, HCM traded as high as $21.92 and as low as $9.77.
The top ETF exchange traded funds that HCM belongs to (by Net Assets): SPDW, DFEM, DFAX, DFSE.
HCM has underperformed the market in the last year with a price return of -10.8% while the SPY ETF gained +12.0%. However, in the short term, HCM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.7% vs +1.5% return in SPY. But in the last 2 weeks, HCM shares have been beat by the market, returning -7.6% compared to an SPY return of -1.4%.
HCM support price is $12.90 and resistance is $13.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCM shares will trade within this expected range on the day.